Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine-Reference-Cited by-同舟云学术

Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine

Published:2017-08-03 Issue:5 Volume:130 Page:655-665
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Cheloni Giulia¹²³^ORCID,Tanturli Michele¹^ORCID,Tusa Ignazia¹³,Ho DeSouza Ngoc²,Shan Yi²,Gozzini Antonella⁴,Mazurier Fréderic⁵^ORCID,Rovida Elisabetta¹³^ORCID,Li Shaoguang²,Dello Sbarba Persio¹³^ORCID

Affiliation:

1. Dipartimento di Scienze Biomediche Sperimentali e Cliniche “Mario Serio”, Università degli Studi di Firenze, Florence, Italy;

2. Department of Medicine, University of Massachusetts Medical School, Worcester, MA;

3. Istituto Toscano Tumori, Tuscany, Italy;

4. Unità Funzionale di Ematologia, Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy; and

5. Équipe Niche Leucémique et Métabolisme Oxydatif, Génétique, Immunothérapie, Chimie et Cancer, Unité Mixte de Recherche 7292, Centre National de la Recherche Scientifique, Université François-Rabelais de Tours, Tours, France

Abstract

Key Points The HIF inhibitor ACF suppresses TKI-insensitive CML stem cells. The FDA-approved drug ACF may represent a novel treatment to prevent CML relapse and, in combination with TKIs, improve remission.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/5/655/1404232/blood745588.pdf

Reference62 articles.

1. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome;Druker;N Engl J Med,2001

2. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro;Graham;Blood,2002

3. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice;Hu;Proc Natl Acad Sci USA,2006

4. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations;Giuntoli;Leukemia,2006

5. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate;Giuntoli;Haematologica,2011

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel targeted therapies in chronic myeloid leukemia;Pharmaceutical Science Advances;2024-09

2. Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies;Journal of Advanced Research;2024-09

3. HIF-2α inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment;Cancer Letters;2024-08

4. Cell-Membrane-Coated Metal–Organic Framework Nanocarrier Combining Chemodynamic Therapy for the Inhibition of Hepatocellular Carcinoma Proliferation;Pharmaceutics;2024-05-05

5. Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels;Medical Oncology;2024-01-12